THE WOODLANDS, Texas,
June 8, 2012 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present
six posters summarizing the mechanism of action and safety of
LX4211, a dual inhibitor of sodium glucose transporters 1 and 2
(SGLT1 and SGLT2) currently in mid-stage development for type 2
diabetes, at the 72nd Scientific Sessions of the American Diabetes
Association (ADA) in Philadelphia,
Pennsylvania during the Saturday morning poster session on
June 9, 2012.
Lexicon has completed dosing in a Phase 2b study of LX4211 in
299 patients with type 2 diabetes and expects to report top-line
results at the end of June.
All posters will be available for download on Saturday morning
from Lexicon's corporate website www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently has
five drug programs in mid-stage development for diabetes, carcinoid
syndrome, irritable bowel syndrome, rheumatoid arthritis and
glaucoma, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has focused
drug discovery efforts on these biologically-validated targets to
create its extensive pipeline of clinical and preclinical programs.
For additional information about Lexicon and its programs, please
visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's clinical development
of LX4211, including characterizations of the results of and
projected timing of clinical trials of such compounds, and the
potential therapeutic and commercial potential of LX4211.
This press release also contains forward-looking statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct clinical development of LX4211, and
preclinical and clinical development of its other potential drug
candidates, advance additional candidates into preclinical and
clinical development, obtain necessary regulatory approvals,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Unless specifically
indicated otherwise, results reported as trends were not
statistically significant. Information identifying such important
factors is contained under "Risk Factors" in Lexicon's annual
report on Form 10-K for the year ended December 31, 2011, as filed with the Securities
and Exchange Commission. Lexicon undertakes no obligation to
update or revise any such forward-looking statements, whether as a
result of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.